Market Overview

Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating

Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating
Related LPCN
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks

Lipocine Inc (NASDAQ: LPCN) is still down 57 percent since the U.S. Food and Drug Administration’s Bone, Reproductive and Urologic Drugs Advisory Committee voted 6-13 on Tlando’s benefit-risk profile.

But one Street analyst is not only undeterred but is encouraged by the drug’s prospects.

The Rating

Empire Asset Management’s Dr. Cathy Reese upgraded Lipocine from Hold to Buy with a $21 price target.

The Thesis

Lipocine decided to initiate FDA-requested trials addressing blood pressure and phlebotomy concerns ahead of the extended May 8 Prescription Drug User Fee Act date. Reese, who acknowledged rumors that Lipocine was investigating the validity of such demands, also questioned the legitimacy of the requests in a Monday note. 

“The FDA has not requested other approved testosterone product sponsors to complete ambulatory blood monitoring trials prior to their approvals, and LPCN’s clinical trial results do not seem to justify a request,” Reese said in a Tuesday note.

If the demands are upheld and Lipocine must complete trials ahead of approval, the PDUFA review cycle would restart and create  delays. Reese is confident in the drug’s potential.

“We believe that Tlando has a high probability of gaining an approval, whether it is on the PDUFA date or once the blood pressure and collection test tube clinical data is generated and reviewed, which we believe should occur in 2018." 

Price Action

At the time of publication, Lipocine was trading up 13.74 percent at $1.49. 

Related Links:

Lipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint

The Companies That Led 2017's Biotech Rally

Latest Ratings for LPCN

Mar 2018Seaport GlobalInitiates Coverage OnBuy
Feb 2018Empire Asset ManagementUpgradesHoldBuy
Jan 2018Canaccord GenuityDowngradesBuyHold

View More Analyst Ratings for LPCN
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Health Care Price Target FDA Analyst Ratings General Best of Benzinga


Related Articles (LPCN)

View Comments and Join the Discussion!

Latest Ratings

TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Veeva Systems Q4 Earnings Preview

Theravance Biopharma Q4 Earnings Outlook